.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
Study from UCLA shows Transpara could help identify hidden breast cancer
.png)
Study from UCLA shows Transpara could help identify hidden breast cancer
New research suggests Transpara Detection can be used to spot cancers radiologist may miss
April 30, 2025
ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves Breast Cancer Detection and Reduces Radiologist Workload
.png)
ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves Breast Cancer Detection and Reduces Radiologist Workload
Only randomized controlled trial of its kind highlights impact of Transpara Breast AI
February 10, 2025
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
Deal brings enhanced capabilities for ScreenPoint’s industry-leading Transpara Breast AI.
January 08, 2025
Transpara Announces New FDA Clearance at RSNA 2024
.png)
Transpara Announces New FDA Clearance at RSNA 2024
SPM Showcases Innovative FDA Cleared Capabilities including Breast Density Assessment and Temporal Comparison to Elevate Radiologist Performance
December 02, 2024
Transpara Improves Cancer Detection by Decreasing False Negative Cancers
.png)
Transpara Improves Cancer Detection by Decreasing False Negative Cancers
Transpara Accurately Identified Half of False Negative Cancers – all Invasive, and Often in Dense Breasts – in a Large Retrospective Study
November 19, 2024
ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO
.png)
ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO
Pieter Kroese appointed as the Chief Executive Officer of ScreenPoint Medical, effective April 25, 2024.
April 05, 2024